CN104042802A - Traditional Chinese medicine composition capable of treating fatty liver - Google Patents
Traditional Chinese medicine composition capable of treating fatty liver Download PDFInfo
- Publication number
- CN104042802A CN104042802A CN201410327304.9A CN201410327304A CN104042802A CN 104042802 A CN104042802 A CN 104042802A CN 201410327304 A CN201410327304 A CN 201410327304A CN 104042802 A CN104042802 A CN 104042802A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fatty liver
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition capable of treating fatty liver, and belongs to the technical field of medicines. The composition comprises the following components: 8-12 parts of rhizoma alismatis, 5-8 parts of oriental wormwood, 8-12 parts of pericarpium citri reticulatae, 8-10 parts of ligusticum wallichii, 3-5 parts of prepared fleece flower root, 15-20 parts of fructus aurantii, 15-20 parts of hawthorn, 8-12 parts of radix bupleuri, 12-15 parts of scutellaria baicalensis, 25-30 parts of rhizoma atractylodis, 5-8 parts of radix paeoniae alba, 5-8 parts of the root of red-rooted salvia, 3-6 parts of semen cassiae, 5-8 parts of wolfberry, and 8-12 parts of liquorice. The composition has a good curative effect in curing fatty liver, and has remarkable clinical promotion value.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine composition and as the application of fatty liver medicine.
Background technology
Fatty liver refers to the pathological changes of fatty overheap in the hepatocyte causing due to a variety of causes.The positive serious threat people's of fatty liver disease health, becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.According to the pathogenic factor of fatty liver, fatty liver is divided into alcoholic fatty liver and non-alcohol fatty liver (NAFLD), and the latter is one of clinical common hepatopathy, and its pathogenesis is still not clear at present.Along with the change of life style and diet structure, the sickness rate of NAFLD obviously increases.Nearly ten years, non-alcohol fatty liver sickness rate in the Asian-Pacific area increases rapidly.China's adult NAFLD prevalence approaches (12%-24%) with Japan, Korea S, and has replaced the primary cause of disease that Chronic Hepatitis B Virus infection (prevalence <7.0%) becomes chronic hepatopathy.And sickness rate is on the increase, morbidity crowd is rejuvenation trend gradually.This disease is often out in the cold in early days in daily life, often delays to abnormal liver function, hepatic fibrosis, even develops into liver cirrhosis.
Although have the Western medicine of much treating for fatty liver on market now, because these blood fat reducing Western medicine mostly have potential hepatotoxicity, and action target spot is single, therefore can not obtain the effect of satisfied treatment.Researching and developing a kind of effective medicine to fatty liver is of great practical significance.
The history of Chinese medicine fatty liver is of long standing and well established, and as an importance of modern hepatopathy Comprehensive Treatment, more and more receives publicity in recent years.People from Chinese traditional herbs, seek single pharmaceutically active ingredient or compound recipe is treated cancer tool challenge.
CN101708236A discloses the application of Hedan tablet at treatment fatty liver, Hedan tablet is to make (consumption is weight portion) by following component: Folium Nelumbinis 60, Radix Salviae Miltiorrhizae 10, Fructus Crataegi 30, Folium Sennae 3, Fructus Psoraleae 10, the dose on the one of being grown up is 3-12 sheet, i.e. 42.375-169.5g crude drug/day.Hedan tablet has the fatty liver mouse model Serum ALT of reduction and TG and hepatic tissue TG value; Hedan tablet can significantly reduce Models of Fatty Liver rat blood serum ALT, reduces serum TG, and TCH and LDL increase serum hdl, reduce hepatic tissue CHO and TG.Meanwhile, can alleviate Models of Fatty Liver mice, rat hepatocytes swelling, steatosis, necrosis and inflammatory cell infiltration degree.Prompting Hedan tablet has fatty liver must curative effect.
CN102596214A discloses a kind of compositions of improving fatty liver, and its effective ingredient is at least one extract in Fructus Lycopersici esculenti herb extract, hemlock chervil extract and Radix Arnebiae extract.
CN1478497 discloses a kind of medicine for the treatment of fatty liver, consists of Rhizoma Alismatis 20-80, Radix Salviae Miltiorrhizae 10-40, Rhizoma Curcumae Longae 10-40, Radix Et Rhizoma Rhei 2-8.This product is used for the treatment of fatty liver, the fatty liver that the fatty liver diseases, particularly Alcoholic particularly causing due to nutritional disorder, heavy drinking, diabetes, infection, Drug damage, metabolism and dyshormonia etc. is the cause of disease.
In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Angle with regard to Chinese medicine sees, the cause of fatty liver is because insobriety, surfeit delicious food savoury, obesity or disorder of emotion or experience epidemic disease caused by damp-heat pathogen poison or weakness due to chronic disease etc. and cause mostly.This diseased region is liver, but closely related with internal organs such as gallbladder, stomach, kidney, spleens.Its pathogeny is the liver failing to maintain the normal flow of QI, dysfunction of the spleen in transportation, and retention of damp-heat in the interior, the turbid pent-up of expectorant, congestion block and finally form phlegm-damp silt resistance knot mutually, and numbness hinders liver venation and forms fatty liver.Therefore, Chinese traditional treatment fatty liver adopts the method for dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness more.
For current fatty liver, there is no very effective Drug therapy, first object of the present invention is to provide the Chinese medicine composition of a kind for the treatment of or prevention fatty liver.Chinese medicine composition of the present invention, according to components by weight percent meter, comprise following component: Rhizoma Alismatis 8-12 part, Herba Artemisiae Scopariae 5-8 part, Pericarpium Citri Reticulatae 8-12 part, Rhizoma Chuanxiong 8-10 part, Radix Polygoni Multiflori Preparata 3-5 part, Fructus Aurantii 15-20 part, Fructus Crataegi 15-20 part, Radix Bupleuri 8-12 part, Radix Scutellariae 12-15 part, Rhizoma Atractylodis 25-30 part, Radix Paeoniae Alba 5-8 part, Radix Salviae Miltiorrhizae 5-8 part, Semen Cassiae 3-6 part, Fructus Lycii 5-8 part, Radix Glycyrrhizae 8-12 part.
Rhizoma Alismatis (rhizome) is cold in nature, has the effect of promoting diuresis to eliminate damp pathogen.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slows down atherogenesis.
Herba Artemisiae Scopariae has clearing away heat-damp and promoting diuresis effect, and modern pharmacology research Herba Artemisiae Scopariae has function of gallbladder promoting, the effects such as liver function protecting, antipyretic, antiinflammatory, blood fat reducing, blood pressure lowering, coronary dilating.
Fructus Aurantii nature and flavor are bitter, acid, be slightly cold, and return lung, spleen, liver, stomach, large intestine channel, and function cures mainly the diseases such as weight after septum pectorale feeling of fullness, distending pain over the hypochondrium, accumulation of food in the stomach and intes tine due to indigestion, distension and fullness in the abdomen, dysentery, proctoptosis, uterine prolapse.
Fructus Crataegi does medicinal with fruit, slightly warm in nature, and sour in the mouth is sweet, enters spleen, stomach, Liver Channel, has the function of promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving.Radix Bupleuri cold nature, bitter in the mouth, pungent, return Liver Channel, gallbladder meridian, has expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy.< < Bencao Jingshu > >: " Radix Bupleuri is shaoyang channel medicine administered to bring out the cold.Stagnation of QI in main trusted subordinate's the intestines and stomach, diet gathers, and cold and heat pathogen, pushes away Chen Zhixin, and except dysphoria with smothery sensation person under the typhoid fever heart, foot-shaoyang gallbladder is also.Gallbladder is peace and quiet mansion, without going out without entering, khan not, emetic should not be given, purgative being prohibited, it is through at half exterior and half interior, therefore method from conciliating, the genus of Herba Sidae Rhombifoliae soup is also.Its property rises and falls apart, and occupies sun, therefore can reach the loose heresy of table also.Pathogens agglomerating is dysphoria with smothery sensation under the heart, and evil loose dysphoria with smothery sensation is explained by oneself.Yang-energy sink, and for diet gathers, sun rises that clearing heat in QI system is up, QI of the spleen and stomach Hang Yang road, and diet gathers from dissipation.All expectorant accumulation of heats are real, evil contrary in the heart, faint breath person between the five internal organs, and the evil disease of viscera connecting with this channel of few YANG excess heat is also.Radix Bupleuri is bitter flat and be slightly cold, can heat extraction eliminating stagnation and induce sweat, therefore can above all diseases.
Radix Scutellariae has heat clearing and damp drying, and removing heat from blood is antiabortive, detoxicating functions.Cure mainly the diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and the effect of improving eyesight, for dampness taste, distension and fullness in the abdomen, cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Control dampness taste, and see the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur.
The Radix Paeoniae Alba enters liver, spleen channel, has nourishing blood to suppress the hyperactive liver, slow middle pain relieving, and yin fluid astringing is received the effect of antiperspirant.Cure mainly the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, is with inferior disease.Radix Salviae Miltiorrhizae promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.
Semen Cassiae, its cold nature, sweet-bitter flavor.Fry use, there is the effect of liver heat removing and eyesight improving, replenishing YIN and removing heat, loosening bowel to relieve constipation.
Radix Polygoni Multiflori Preparata: the i.e. Radix Polygoni Multiflori that processing system is ripe.Radix Polygoni Multiflori Preparata is warm in nature, sweet-bitter flavor.The traditional Chinese medical science thinks that Radix Polygoni Multiflori Preparata is that tonification is simply kept fit, the good medicine of life lengthening.Modern experiment confirmation, the Radix Polygoni Multiflori has the effect of blood fat reducing, blood sugar lowering, vessel softening and blood pressure lowering.
Fructus Lycii: sweet in the mouth, property is flat.Chinese medicine think its can tonifying liver the moon, nourishing the liver blood, replenishing vital essence to improve eyesight.Modern pharmacological research proves: Fructus Lycii energy blood sugar lowering, and suppress fat and deposit in hepatocyte, promote hepatocyte newborn, and have antihypertensive effect.
Rhizoma Alismatis and Herba Artemisiae Scopariae can play damp eliminating and protect the liver.Pericarpium Citri Reticulatae, Fructus Aurantii and Fructus Crataegi can promoting digestion and invigorating the stomach, eliminate distension and fullness in the abdomen symptom.The tender enough heat clearing and damp drying of Radix Bupleuri and Radix Scutellariae, eliminating stagnation are induced sweat.The Radix Paeoniae Alba and Radix Salviae Miltiorrhizae can nourishing blood to suppress the hyperactive liver, nourishing blood to tranquillize the mind.
The present invention combines above-mentioned all taste Chinese medicine and parts by weight thereof, plays the effect of dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness.Preferred condition is the enhancing of medication effect after drug matching is used.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by the raw material of following weight portion: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 5 parts of Radix Polygoni Multiflori Preparata, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 6 parts of Semen Cassiaes, 5 parts of Fructus Lycii, 10 parts, Radix Glycyrrhizae.
The method of preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned components by weight percent, add the water of 5-15 times of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filters, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees Celsius, and adding ethanol is 60-90%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, obtain.The above-mentioned Chinese medicine composition of the present invention can further be prepared into conventional clinically pharmaceutical preparation, is preferably mixture, tablet, capsule.The described preparation method of making mixture, tablet, capsule is prior art.
Decoction of the present invention, filtrate decompression concentrate, simmer down to this area common technology, and temperature, pressure are not particularly limited.
The invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment or prevention fatty liver medicine.The present invention tests the treatment of Making Rat Models of Nonalcoholic by investigating Chinese medicine composition of the present invention, find that Chinese medicine composition provided by the invention can obviously reduce AST and the ALT of Rats with Fatty Liver model, TG, TC and the LDL-C of fatty rat model can be significantly reduced, and the liver index of rat model can be significantly reduced.This acts on comprehensively while showing Chinese medicine composition of the present invention to treatment or prevention fatty liver disease, has obvious synergism, has obtained unforeseeable curative effect of medication.
In a word, the present invention compared with prior art, has the activity of fine treatment fatty liver.When the present invention uses as fatty liver medicine, drug effect is comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain the effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, and sb.'s illness took a favorable turn can to make rapidly Patients with Fatty Liver; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good application prospect.
The specific embodiment
By the specific embodiment, further describe the present invention below, but the present invention is not limited only to following examples.Within the scope of the invention or within not departing from flesh and blood of the present invention and scope, Chinese medicine composition of the present invention is suitably improved, replaces the component that effect is identical, within will become apparent to those skilled in the art that they are all deemed to be included in scope of the present invention.
first, the preparation of Chinese medicine composition of the present invention
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 grams of Rhizoma Alismatis, 6 grams of Herba Artemisiae Scopariaes, 8 grams of Pericarpium Citri Reticulataes, 10 grams of Rhizoma Chuanxiongs, 5 grams of Radix Polygoni Multiflori Preparata, 18 grams of Fructus Aurantiis, 20 grams of Fructus Crataegis, 12 grams of Radix Bupleuri, 12 grams of Radix Scutellariaes, 5 grams of Semen Cassiaes, 30 grams of Rhizoma Atractylodis, 6 grams of the Radix Paeoniae Albas, 8 grams of Fructus Lycii, 6 grams of Radix Salviae Miltiorrhizaes, 10 grams, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 10 times of medical material gross weight, soak 60 minutes, decoct 4 times, each 0.5 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 86%(v/v to containing alcohol amount), standing 24 hours, get supernatant, recovery ethanol is concentrated, adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: 8 grams of Rhizoma Alismatis, 8 grams of Herba Artemisiae Scopariaes, 8 grams of Pericarpium Citri Reticulataes, 10 grams of Rhizoma Chuanxiongs, 5 grams of Radix Polygoni Multiflori Preparata, 20 grams of Fructus Aurantiis, 15 grams of Fructus Crataegis, 12 grams of Radix Bupleuri, 12 grams of Radix Scutellariaes, 30 grams of Rhizoma Atractylodis, 6 grams of the Radix Paeoniae Albas, 8 grams of Semen Cassiae, 8 grams of Fructus Lycii, 6 grams of Radix Salviae Miltiorrhizaes, 12 grams, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 8 times of medical material gross weight, soak 45 minutes, decoct 2 times, each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 78%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 grams of Rhizoma Alismatis, 6 grams of Herba Artemisiae Scopariaes, 10 grams of Pericarpium Citri Reticulataes, 10 grams of Rhizoma Chuanxiongs, 5 grams of Radix Polygoni Multiflori Preparata, 20 grams of Fructus Aurantiis, 20 grams of Fructus Crataegis, 10 grams of Radix Bupleuri, 15 grams of Radix Scutellariaes, 30 grams of Rhizoma Atractylodis, 5 grams of the Radix Paeoniae Albas, 6 grams of Radix Salviae Miltiorrhizaes, 6 grams of Semen Cassiaes, 5 grams of Fructus Lycii, 10 grams, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 5 times of medical material gross weight, soak 30 minutes, decoct 3 times, each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 90%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
the treatment of embodiment 4 Chinese medicine composition of the present invention to non-alcoholic fatty liver disease
The preparation of 1 nonalcoholic fatty liver model
SD rat, male, body weight 240 ± 20g, adopts the method modeling of the high lipoprotein emulsion associating of gavage lumbar injection tetracycline.Except Normal group, all the other each groups give lumbar injection tetracycline 150mg/kg on the 1st day in modeling, after every 6d lumbar injection tetracycline 110mg/kg1 time, totally 6 times.Except normal group, every group in the high lipoprotein emulsion of every morning 9:30 gavage, dosage 10mlkg
-1d
-1.High lipoprotein emulsion formula: Adeps Sus domestica 20g, cholesterol 10g, fructose 5g, sucrose 5g, cholate 1g, sodium glutamate 1g, propylene glycol 15ml, 2ml Tween 80, distilled water is settled to 100ml.Gavage continues 8W to high fat breast.
2 grouping and administrations
Rat model adaptability was raised after 1 week, was divided at random normal group, model group and administration group, and the situation of specifically dividing into groups is as follows, 5 every group.Every afternoon is gavage medicine during 14:00, and dosage is as follows:
Normal group: gavage gives the distilled water of same volume;
Model control group: gavage gives the distilled water of same volume;
Silibinin group: gavage gives 25mg/(kg.d) silibinin;
1 group of embodiment: gavage gives 25mg/(kg.d) the prepared Chinese medicine composition mixture of the embodiment of the present invention 1;
2 groups of embodiment: gavage gives 25mg/(kg.d) the prepared Chinese medicine composition mixture of the embodiment of the present invention 2;
3 groups of embodiment: gavage gives 25mg/(kg.d) the prepared Chinese medicine composition mixture of the embodiment of the present invention 3;
3 detect index
After last administration, pentobarbital sodium anesthetized rat, dissects, and abdomen cardinal vein is got hematometry biochemical indicator, gets liver and weighs.
3.1. blood fat
Result of the test shows (referring to table 1), the level of the T-CHOL of embodiment group, triglyceride, HDL-C and low-density lipoprotein cholesterol has been compared significant difference or utmost point significant difference with fatty liver model of rats group, compare with silibinin group and also there is significant difference or utmost point significant difference (except hdl level), this illustrates Chinese medicine composition of the present invention, on fatty liver model of rats, on reduction TG, TC and LDL-C, obtained good effect.
The impact of table 1 Chinese medicine composition of the present invention on rat fat
With model group comparison,
*p < 0.05; With model group comparison,
*p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
3.3. liver index
Result of the test shows (referring to table 2), Models of Fatty Liver group rats'liver index has been compared utmost point significant difference with normal group, the liver index of the rat of each administration group has been compared utmost point significant difference with model group, especially, 3 groups of embodiment have compared significant difference or utmost point significant difference with silibinin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention, on fatty liver model of rats, has been obtained good synergism in this index of reduction liver index.
The impact of table 2 Chinese medicine composition of the present invention on Rats Organs and Tissues index
With normal group comparison,
$p < 0.05; With normal group comparison,
$$p < 0.01;
With model group comparison,
*p < 0.05; With model group comparison,
*p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
3.3 liver function
Result of the test shows (referring to table 3), Models of Fatty Liver group rat blood serum ALT, AST content are compared with normal group significantly and are raise, the rat blood serum ALT of each administration group, AST content are compared obvious decline with model group, especially, 3 groups of embodiment compare with model group has utmost point significant difference, compared utmost point significant difference with silibinin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention has been obtained synergitic effect on to the prevention of rat fat liver or treatment.
The impact of table 3 Chinese medicine composition of the present invention on rat model liver function
With model group comparison,
*p < 0.05; With model group comparison,
*p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
Claims (5)
1. treat a Chinese medicine composition for fatty liver, it is characterized in that comprising each component as next weight fraction: Rhizoma Alismatis 8-12 part, Herba Artemisiae Scopariae 5-8 part, Pericarpium Citri Reticulatae 8-12 part, Rhizoma Chuanxiong 8-10 part, Radix Polygoni Multiflori Preparata 3-5 part, Fructus Aurantii 15-20 part, Fructus Crataegi 15-20 part, Radix Bupleuri 8-12 part, Radix Scutellariae 12-15 part, Rhizoma Atractylodis 25-30 part, Radix Paeoniae Alba 5-8 part, Radix Salviae Miltiorrhizae 5-8 part, Semen Cassiae 3-6 part, Fructus Lycii 5-8 part, Radix Glycyrrhizae 8-12 part.
2. a kind of Chinese medicine composition for the treatment of fatty liver as claimed in claim 1, is characterized in that comprising each component as next weight fraction: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 5 parts of Radix Polygoni Multiflori Preparata, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 6 parts of Semen Cassiaes, 5 parts of Fructus Lycii, 10 parts, Radix Glycyrrhizae.
3. a kind of Chinese medicine composition for the treatment of fatty liver as claimed in claim 1, is characterized in that: described pharmaceutical composition is mixture, tablet, capsule.
4. a method of preparing the Chinese medicine composition of the treatment fatty liver as described in claim 1,2 or 3, is characterized in that it comprises the following steps: get each medical material, add the water of 5-15 times of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and adding ethanol is 60-90%v/v to containing alcohol amount, standing 24 hours, get supernatant, reclaim ethanol to concentrated, obtain.
5. the purposes in fatty liver medicine is treated or prevented to the Chinese medicine composition described in claim 1,2 or 3 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410327304.9A CN104042802A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicine composition capable of treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410327304.9A CN104042802A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicine composition capable of treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042802A true CN104042802A (en) | 2014-09-17 |
Family
ID=51496525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410327304.9A Pending CN104042802A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicine composition capable of treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042802A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104928136A (en) * | 2015-06-30 | 2015-09-23 | 青岛浩大海洋保健食品有限公司 | Baobei compound wine with blood lipid regulating function |
| CN105168795A (en) * | 2015-07-15 | 2015-12-23 | 济南大学 | Oral drug for treating fatty liver and supplementing nutrition |
| CN105535826A (en) * | 2015-12-29 | 2016-05-04 | 上海珍岛信息技术有限公司 | Pharmaceutical composition for treating cat fatty liver and preparation method thereof |
| CN105853691A (en) * | 2016-06-17 | 2016-08-17 | 李登 | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof |
| CN106668775A (en) * | 2017-02-17 | 2017-05-17 | 成都市飞龙水处理技术研究所青白江第分所 | Capsule medicine for treating fatty liver and preparation method thereof |
| CN107582714A (en) * | 2017-06-01 | 2018-01-16 | 合肥远志医药科技开发有限公司 | A kind of formula and its extraction process for dispersing liver and promoting blood circulation |
| CN107753855A (en) * | 2017-11-07 | 2018-03-06 | 玉林市中医医院 | A kind of clearing away liver fire and reducing fat Chinese medicine preparation and preparation method thereof |
| CN108057110A (en) * | 2018-02-01 | 2018-05-22 | 重庆跃龙生物制药有限公司 | Chinese medicine composition for treating fatty liver and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
-
2014
- 2014-07-10 CN CN201410327304.9A patent/CN104042802A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
Non-Patent Citations (1)
| Title |
|---|
| 潘丰满等: "柴胡疏肝散治疗非酒精性脂肪肝82例临床观察", 《时珍国医国药》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104928136A (en) * | 2015-06-30 | 2015-09-23 | 青岛浩大海洋保健食品有限公司 | Baobei compound wine with blood lipid regulating function |
| CN105168795A (en) * | 2015-07-15 | 2015-12-23 | 济南大学 | Oral drug for treating fatty liver and supplementing nutrition |
| CN105535826A (en) * | 2015-12-29 | 2016-05-04 | 上海珍岛信息技术有限公司 | Pharmaceutical composition for treating cat fatty liver and preparation method thereof |
| CN105853691A (en) * | 2016-06-17 | 2016-08-17 | 李登 | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof |
| CN106668775A (en) * | 2017-02-17 | 2017-05-17 | 成都市飞龙水处理技术研究所青白江第分所 | Capsule medicine for treating fatty liver and preparation method thereof |
| CN107582714A (en) * | 2017-06-01 | 2018-01-16 | 合肥远志医药科技开发有限公司 | A kind of formula and its extraction process for dispersing liver and promoting blood circulation |
| CN107753855A (en) * | 2017-11-07 | 2018-03-06 | 玉林市中医医院 | A kind of clearing away liver fire and reducing fat Chinese medicine preparation and preparation method thereof |
| CN108057110A (en) * | 2018-02-01 | 2018-05-22 | 重庆跃龙生物制药有限公司 | Chinese medicine composition for treating fatty liver and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN102488850B (en) | Traditional Chinese medicinal composition for treating alcoholic fatty liver and preparation method thereof | |
| CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN104013926A (en) | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| CN104338043B (en) | A kind of medicine for improving immunity and preparation method thereof | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103041256B (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
| CN104784624A (en) | Traditional Chinese medicine for treating dyspepsia | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103041257B (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN103041255B (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN104857210A (en) | Traditional Chinese medicine combination preparation for treating fatty liver and preparation method thereof | |
| CN103705731B (en) | A kind of Chinese medicine composition for the treatment of chronic alcoholic toxic liver disease | |
| CN103007204B (en) | Chinese medicinal composition for treating hepatofibrosis | |
| CN104758676A (en) | Medicine for treating damp-heat in resistance-type epigastric pain | |
| CN104771553A (en) | Invigorating spleen and kidney preparation for treatment of gastric cancer and preparation method thereof | |
| CN104127826A (en) | Traditional Chinese medicine composition for treating chronic alcoholic liver disease | |
| CN104666999A (en) | Traditional Chinese medicine formula capable of reducing blood pressure | |
| CN103285130B (en) | Chinese medicine composition for liver cancer treatment and preparing method thereof | |
| CN103041258B (en) | Chinese materia medica preparation for curing respiratory tract infection with poor appetite of children | |
| CN105362966A (en) | Method for preparing traditional Chinese medicine preparation for treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |
|
| RJ01 | Rejection of invention patent application after publication |